Location: United States, Kentucky, Newport
Employees: 51-200
Total raised: $25M
Investors 1
| Date | Name | Website |
| 14.05.2021 | EW Healthc... | ewhealthca... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.07.2007 | - | $25M | - |
Mentions in press and media 7
| Date | Title | Description |
| 30.10.2009 | Xanodyne Raises $50M in Equity Financing to Support Emerging Product Portfolio | Newport, Kentucky-based Xanodyne Pharmaceuticals, Inc., a pharmaceutical company with both development and commercial capabilities focused on women’s healthcare and pain management, completed a $50m in equity financing. The round was led by... |
| 11.06.2009 | Sans IPO, Bayhill secures $350M in Genentech licensing deal | Months after giving up on its IPO hopes last year — when the market was especially brutal for lifescience companies — Bayhill Therapeutics has landed a licensing deal worth $25 million in upfront cash and equity with Genentech. It could bri... |
| 05.06.2009 | Xanodyne Pharmaceuticals completes $38m funding round | Xanodyne previously raised around $232m in venture funding, including a $170m Series A-1 round in 2005, which helped fin |
| 30.03.2009 | Essex Woodlands raises almost $1B for life science investments | Essex Woodlands Health Ventures announced today that it brought in $900 million for its eighth fund, one of the largest sums ever raised by a health care-focused venture firm, according to the Wall Street Journal — even more impressive cons... |
| 27.10.2008 | Xanodyne newest pharm co. to cancel IPO | Xanodyne joins a growing number of biopharmaceutical and life science companies calling it quits on going public, at least for now. The Newport, Ky.-based firm withdrew its filing on Friday, citing poor market conditions — it had been waiti... |
| 12.11.2007 | IPOs: Biotech ChemoCentryx and specialty-pharma Xanodyne head for the public market | ChemoCentryx files for $58M IPO to fund autoimmune, inflammation drug — Mountain View, Calif.-based ChemoCentryx, a biotech focused on new small-molecule drugs that affect a class of biochemical signals known as chemokines, filed to raise $... |
| 27.07.2007 | Xanodyne raises $25M for narcotics and vitamins | Xanodyne Pharmaceuticals, a Newport, Ky., specialty-pharmaceutical company specializing in narcotic pain drugs and prenatal vitamins, raised $25 million in an extension of a 2005 recapitalization, VentureWire reports (subscription required)... |